One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
about
Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter studyClinical applications of pulmonary delivery of antibioticsBackground and EpidemiologyOral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.State of progress in treating cystic fibrosis respiratory disease.Clinical significance of microbial infection and adaptation in cystic fibrosis.Managing acute on chronic respiratory failure: a guide to non-invasive ventilation.Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis.Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onsetEffects of lung transplantation on inpatient end of life care in cystic fibrosis.Severe hypercapnia in critically ill adult cystic fibrosis patients.Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.Update in transplantation 2005.Update in cystic fibrosis 2005Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.Intensive care management of the patient with cystic fibrosis.Update on antibiotics for infection control in cystic fibrosis.Noninvasive ventilation in cystic fibrosis.Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.Aerobic fitness is associated with lower risk of hospitalization in children with cystic fibrosis.A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.Critical illness among adults with cystic fibrosis in Texas, 2004-2013: Patterns of ICU utilization, characteristics, and outcomes.Inhalation Techniques Used in Patients with Respiratory Failure Treated with Noninvasive Mechanical Ventilation.Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
P2860
Q25257344-452B7328-02BA-4C73-AE54-B2F857F5493DQ26996053-1BF46727-C887-45A7-A7A2-53A13FD96622Q30248742-5CDD9334-0C61-43EE-A06F-B5485B85D69FQ33725822-57ACC416-F8B3-4608-B116-D83D45E7F959Q33836302-6D7BE057-3A11-4F01-8B62-F2375D2B963DQ34353683-F5E5C7AA-7ED1-45F4-A47C-E0A4B6AFF699Q34375926-59F32AB4-1F07-461F-AE7C-CCF366EF5E71Q34491552-6EE58DCD-EE02-4781-8CF7-5D6010794537Q34824784-A4383F9C-B15E-47D5-8BA4-5BC12B1A3533Q35107086-50B619ED-39B5-474F-BAFA-C34FB129E8F3Q35143420-DA3E5014-322B-40D4-8381-1CAB76DE6629Q35379293-BC5EEF42-F34C-4305-9ACC-D5F3114B073FQ35756954-EF8EC9F0-AE8A-4831-ACE5-41AC7AC80585Q36237974-5EC7B881-08E8-40E3-93E6-96B121C0F3CEQ36416045-08A89CAF-5646-4759-BA7E-65CD12339B10Q36457176-6F06466B-097E-4208-9C89-07FC973020ACQ36658777-2FA982E2-4301-4071-8569-21A6DAD1CE4FQ36771148-36BF903C-6709-482B-9FB5-5F6E6DE47186Q37149666-384AD627-8AEE-429B-87F7-3F6E7085FC8FQ37608274-F33B6E32-177A-498A-9053-85940E86441BQ37729990-89427156-3CC4-47A9-915D-4B2B8FB15DD8Q39800405-B6485020-F906-4BCA-BFC1-87732C5E5546Q42768766-15637F8F-3BF6-4816-8DB3-F9F7E0A0BC43Q43892015-F7AFECD4-07DB-40D7-922B-94A85E29FCB3Q44016904-D59238CB-BCEA-4090-92FC-99E0AA03ABD5Q47408851-C820B134-84E2-403D-92AA-F1441E293E8DQ55421437-E2958D7C-148B-416B-AC9D-DE1FAF706E80Q58795676-4DFF6721-62F2-43DD-8151-16A00B16010B
P2860
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
@en
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
@nl
type
label
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
@en
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
@nl
prefLabel
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
@en
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
@nl
P2093
P2860
P1476
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis
@en
P2093
Daniel Dusser
Dominique Hubert
Jean-François Dhainaut
Joël Coste
Madiha Ellaffi
P2860
P304
P356
10.1164/RCCM.200405-667OC
P407
P577
2004-10-22T00:00:00Z